Home

arrow iconNewsarrow iconarrow icon

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

By FertilityIn

12 Oct 2026

1 min read

AI-Powered Embryo Assessment by Alife Health

AI-Powered Embryo Assessment by Alife Health

A San Francisco-based digital health company has crossed a landmark regulatory threshold in fertility medicine. Alife Health announced on May 28, 2026, that its product Embryo Predict has received clearance from the U.S. Food and Drug Administration, marking a significant step forward in AI-powered embryo assessment during in vitro fertilization. The tool is designed to give fertility specialists a data-driven, adjunctive layer of insight when making one of the most consequential decisions in the IVF process: which embryo to select for transfer.



IVF remains one of the most emotionally and financially demanding medical journeys a person can undergo. On average, patients in the U.S. go through three cycles before achieving a successful pregnancy. A core challenge has long been the selection of the right embryo a decision that, despite the expertise of seasoned clinicians, carries a surprisingly high degree of variability. Published research found a 34.6% disagreement rate among fertility specialists selecting the top embryo for transfer, rising to 44% when patients had three or more embryos to choose from.


That inconsistency underscores the need for standardized, evidence-backed tools. Embryo Predict addresses this gap directly. The system analyzes images of each embryo using artificial intelligence, drawing on patterns learned from thousands of embryos and their outcomes across clinics, geographies, and patient profiles worldwide. It integrates with microscopes and imaging systems already in use in fertility labs, with no new hardware required. Indicated for Day 5, 6, and 7 blastocyst-stage embryos deemed suitable for transfer, the device provides adjunctive information when multiple embryos are candidates for transfer or freezing based on standard morphological assessment.


The FDA clearance was backed by a prospective, randomized, multi-center clinical trial conducted at seven leading centers across the United States, enrolling 440 patients and evaluating AI-assisted embryo selection against standard evaluation alone. Melissa Teran, CEO and co-founder of Alife Health, placed the milestone in the context of the company's six-year journey: "Six years ago, we set out to put IVF's wealth of clinical data to work in a way the field had never seen before. Today, that work is validated. This clearance reflects years of rigorous clinical research and the trust of the clinicians and institutions who partnered with us. For the first time, the collective insight from thousands of embryos and outcomes around the world is available to every embryologist, at every transfer decision." Alison Bartolucci, Ph.D., HCLD, Chief Scientific Officer at First Fertility, echoed the significance of the development: "As the field of reproductive medicine advances, we have a responsibility to bring the most rigorous, evidence-based tools into our labs. Alife's Embryo Predict does exactly that. It layers AI-driven insight onto the clinical expertise already in the room, giving embryologists adjunctive AI information for one of the most consequential decisions in a patient's IVF journey."


Beyond the U.S. market, Embryo Predict already holds CE Mark under the European Union Medical Device Regulation and is now commercially available across the U.S., Europe, and the U.K. The combination of multi-jurisdictional regulatory approvals and a randomized clinical trial foundation positions Alife Health's AI-powered embryo assessment platform as one of the more rigorously validated entrants in the growing field of AI-assisted reproductive medicine.

121 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Fertility Treatment Coverage Gap Revealed by Stork Foundation

Fertility Treatment Coverage Gap Revealed by Stork Foundation

The Stork Foundation for Infertility received a record 1,076 grant applications in 2026, with data revealing that 85% of applicants have no fertility treatment coverage for the care they are pursuing. Average anticipated next treatment costs stand at 19,149 USD, with 39% having already spent more than 10,000 USD out of pocket.

ART

1 min read

Future Health Abu Dhabi Opens Digital Health Innovation Challenge 2026

Future Health Abu Dhabi Opens Digital Health Innovation Challenge 2026

Future Health, A Global Initiative by Abu Dhabi has launched the Future Health Digital Health Innovation Challenge 2026, inviting global innovators to develop AI, software, and connected technology solutions across fertility, population health, and well-being. Three finalists will share USD 105,000 at GITEX 2026, with selected solutions eligible for incubation and scale.

ART

1 min read

La Trobe University and GonGlobal Partner to Advance AI-Driven Fertility Care Through Digital Twin Technology

La Trobe University and GonGlobal Partner to Advance AI-Driven Fertility Care Through Digital Twin Technology

La Trobe University and GonGlobal have entered a strategic collaboration to develop and validate AI and digital twin technologies for ART and IVF. The partnership will build AI-driven fertility care tools, including cohort matching digital twins and deep-learning models, to predict pregnancy outcomes and support personalised clinical decision-making.

ART

1 min read

The World Egg and Sperm Bank Joins IVI Institute to Widen Access to Reproductive Solutions Globally

The World Egg and Sperm Bank Joins IVI Institute to Widen Access to Reproductive Solutions Globally

IVI Institute has announced the acquisition of The World Egg and Sperm Bank (TWESB), founded in 2004 and operating from Scottsdale, Arizona. The move expands access to reproductive solutions for patients and clinics across the United States and Australia, combining TWESB’s network of 500+ screened donors with IVI Institute’s global clinical and scientific infrastructure.

ART

1 min read

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

UK’s First Testicular Tissue Transplant Offers Hope for Fertility Preservation

Doctors at NHS Lothian in Edinburgh have performed the UK’s first testicular tissue transplant, reimplanting tissue frozen before chemotherapy in a 19-year-old patient with a serious blood disorder. The testicular tissue transplant, only the second reported worldwide, could eventually give thousands of young boys a realistic path to future fatherhood.

ART

1 min read

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

AiVA AI Assistant: IVI RMA Launches Fertility AI Platform

Flora Fertility and Clue have announced the Flora Clue fertility partnership, connecting the first individually owned fertility insurance platform with the world’s leading women-led cycle tracking app. FLORA policyholders receive complimentary Clue Plus access, while Clue’s community of over 100 million members gains early exposure to proactive fertility financial planning.

ART

1 min read

WHO Issues First Global Guideline on Infertility Care

WHO Issues First Global Guideline on Infertility Care

The World Health Organization releases its first comprehensive, evidence-based global guideline for infertility prevention, diagnosis, and treatment. Addressing one in six people of reproductive age worldwide, the guideline emphasizes equity, human rights, and standardized interventions to improve access to fertility care globally.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address